V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 190009421 | 190002707 | null | null | null | null | 2019-11-20 | Oxaliplatin + Modified de Gramont | null | null | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100234026 |
| 190009429 | 190002711 | 1.7 | 58 | Curative (C) | 2017-12-05 | 2017-12-13 | EW EuroEwing 2012 Arm B VDC | 01 | N | EW EUROEWING 2012 ARM B VDC | 100402223 |
| 190009431 | 190002712 | 1.81 | 64.1 | Curative (C) | 2019-08-18 | 2019-08-23 | LANREOTIDE | N | N | NB HRNBL-1 COJEC IND COURSE A | 100098831 |
| 190009436 | 190002714 | 1.75 | 80.7 | null | 2018-12-18 | 2018-12-27 | LANREOTIDE | 02 | null | EW EUROEWING 2012 ARM B IE | 101506781 |
| 190009440 | 190002716 | 1.66 | 82.1 | Palliative (P) | 2018-03-18 | 2018-03-19 | EOX | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100102281 |
| 190009444 | 190002718 | null | null | null | null | 2018-12-25 | Dox + HD Mtx (post PAM) | null | null | DOXORUBICIN + METHOTREXATE | 101018667 |
| 190009447 | 190002719 | null | 60 | Curative (C) | 2016-11-20 | 2016-11-24 | CISPLATIN + GEMCITABINE | 02 | N | CISPLATIN + ETOPOSIDE | 100371144 |
| 190009448 | 190002720 | 1.67 | 52.2 | Neo-adjuvant (N) | 2020-04-09 | 2020-04-17 | OST Euramos 1 Closed Trial - AP | 02 | N | OST AP | 101511886 |
| 190009451 | 190002722 | 0 | 51 | Adjuvant (A) | 2016-03-15 | 2016-04-03 | MIFAMURTIDE | 02 | N | DOXORUBICIN + METHOTREXATE | 100755150 |
| 190009459 | 190002724 | null | null | null | null | 2018-02-12 | ECX | null | null | EURO-EWING | 101373999 |
| 190009462 | 190002725 | 1.58 | 84.8 | Curative (C) | 2018-04-13 | 2018-04-15 | Irinotecan + Modified De Gramont | null | N | EW EUROEWING 2012 ARM A VAI | 101653072 |
| 190009468 | 190002727 | 0 | 46 | Palliative (P) | 2016-07-31 | 2016-07-31 | VIDE | 2 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100891838 |
| 190009469 | 190002728 | 1.72 | 75.5 | Palliative (P) | 2017-10-10 | 2017-10-17 | LANREOTIDE | N | N | EURO-EWING | 100346219 |
| 190009470 | 190002729 | 1.57 | 65.05 | null | 2019-06-10 | 2019-06-25 | EW EuroEwing 2012 Arm B VDC | N | null | EW EUROEWING 2012 ARM B VDC | 101465824 |
| 190009473 | 190002730 | 1.69 | 89 | Palliative (P) | 2020-05-27 | 2020-05-27 | Trial Unspecified | 02 | N | EW EUROEWING 2012 ARM A VIDE | 100708468 |
| 190009475 | 190002731 | null | null | null | null | 2016-07-07 | Cisplatin + Doxorubicin | null | null | CISPLATIN + DOXORUBICIN | 101755166 |
| 190009480 | 190002732 | null | null | null | null | 2018-02-22 | CARBOPLATIN | null | null | DOXORUBICIN + METHOTREXATE | 100637315 |
| 190009485 | 190002733 | 1.7 | 74.8 | Palliative (P) | 2017-05-01 | 2017-05-06 | MAP | 02 | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 100879122 |
| 190009493 | 190002735 | null | null | null | null | 2018-12-10 | OST Euramos 1 Closed Trial - AP | null | null | OST AP | 101369193 |
| 190009496 | 190002736 | 1.5 | 52.6 | Neo-adjuvant (N) | 2018-05-19 | 2018-05-23 | Carboplatin + Liposomal Doxorubicin | 02 | N | VIDE | 100798783 |
| 190009500 | 190002738 | 1.57 | 84.9 | Neo-adjuvant (N) | 2016-08-01 | 2016-08-15 | Cisplatin + Doxorubicin | 02 | N | CISPLATIN + DOXORUBICIN | 100410213 |
| 190009501 | 190002739 | 0 | 30.3 | 03 | 2018-07-27 | 2018-08-21 | EW EuroEwing 2012 Arm B VDC | 02 | Y | EW EUROEWING 2012 ARM B VDC | 100690564 |
| 190009503 | 190002740 | 1.61 | 24.5 | Palliative (P) | 2018-11-22 | 2018-11-22 | DHAP | 01 | N | TRIAL UNSPECIFIED | 100485177 |
| 190009505 | 190002741 | null | null | null | null | 2018-07-22 | Cetuximab + Radiotherapy Load | null | null | MAP | 100154257 |
| 190009509 | 190002742 | 0 | 23.6 | Curative (C) | 2019-04-02 | 2019-04-16 | ECX | 02 | null | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100611382 |
| 190009510 | 190002743 | null | null | null | null | 2016-10-19 | EW EuroEwing 2012 Arm B VDC | null | null | EW EUROEWING 2012 ARM B VDC | 100547892 |
| 190009511 | 190002744 | 1.63 | 81 | Curative (C) | 2018-04-24 | 2018-05-11 | Cisplatin + Doxorubicin | 02 | Y | CISPLATIN + DOXORUBICIN | 101066893 |
| 190009512 | 190002745 | null | null | null | null | 2018-04-19 | EW EuroEwing 99 : VIDE | null | null | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101738123 |
| 190009517 | 190002747 | 0 | 41.4 | Neo-adjuvant (N) | 2017-03-28 | 2017-04-24 | Cisplatin + Doxorubicin | 02 | N | CISPLATIN + DOXORUBICIN | 101378397 |
| 190009519 | 190002748 | 1.4 | 61.2 | Curative (C) | 2016-10-13 | 2016-10-15 | VIDE | 02 | Y | VIDE | 101706024 |
| 190009521 | 190002749 | null | null | null | null | 2016-03-29 | Doxorubicin + Ifosfamide | null | null | DOXORUBICIN + METHOTREXATE | 100923744 |
| 190009522 | 190002750 | null | null | null | null | 2020-04-19 | OST Euramos 1 Closed Trial - Ai | null | null | TRIAL | 101045682 |
| 190009525 | 190002751 | 1.72 | 53 | Neo-adjuvant (N) | 2016-03-23 | 2016-04-09 | EW EuroEwing 2012 Arm B VDC | 01 | N | EW EUROEWING 2012 ARM B VDC | 100781139 |
| 190009528 | 190002752 | 1.77 | 65 | Palliative (P) | 2020-01-07 | 2020-01-07 | PAM x 2 pre-surgery (cycles 1&2) | 02 | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 101002105 |
| 190009532 | 190002754 | null | null | null | null | 2016-07-04 | EOX | null | null | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100808837 |
| 190009542 | 190002757 | null | null | null | null | 2016-12-11 | Cisplatin + Doxorubicin | null | null | CISPLATIN + DOXORUBICIN | 100114080 |
| 190009543 | 190002758 | null | null | null | null | 2019-12-22 | Dox + HD Mtx (post PAM) | null | null | NOT MATCHED | 101218469 |
| 190009544 | 190002759 | 1.66 | 86 | Curative (C) | 2018-07-05 | 2018-07-12 | VDC | null | Y | METHOTREXATE + VINBLASTINE | 100979755 |
| 190009548 | 190002762 | null | null | null | null | 2016-11-05 | Docetaxel+Gemcitabine (no prior RT) | null | null | DOXORUBICIN + IFOSFAMIDE | 100759437 |
| 190009551 | 190002763 | null | null | null | null | 2018-07-07 | EOX | null | null | DOXORUBICIN | 101372859 |
| 190009556 | 190002764 | null | null | null | null | 2020-02-11 | OST Euramos 1 Closed Trial - AP | null | null | OST AP | 100498543 |
| 190009559 | 190002765 | 1.84 | 74 | Curative (C) | 2018-07-13 | 2018-07-16 | EW EuroEwing 2012 Arm A VIDE | null | Y | NOT MATCHED | 101690442 |
| 190009561 | 190002767 | 0 | 9.2 | Palliative (P) | 2019-11-11 | 2019-11-26 | Cetuximab 7 day (Cycle 1) | 02 | N | GC INT GUIDE EXCRANIAL GERMCELL JEB | 101277746 |
| 190009564 | 190002768 | null | null | null | null | 2017-08-11 | Cisplatin + Doxorubicin | null | null | CISPLATIN + DOXORUBICIN | 100808875 |
| 190009566 | 190002769 | null | null | null | null | 2019-08-13 | OST Euramos 1 Closed Trial - AP | null | null | OST AP | 100417776 |
| 190009570 | 190002770 | 1.6 | null | Curative (C) | 2019-06-22 | 2019-07-03 | Cisplatin + Doxorubicin | 02 | N | CISPLATIN + DOXORUBICIN | 100245391 |
| 190009571 | 190002771 | null | null | null | null | 2015-04-21 | ECX | null | null | CARBOPLATIN + DOCETAXEL | 101767147 |
| 190009576 | 190002773 | 1.78 | 96.4 | null | 2018-02-05 | 2018-02-05 | Cisplatin + Etoposide po&iv 3 day | N | null | TRIAL UNSPECIFIED | 101692741 |
| 190009583 | 190002775 | 0 | 86.2 | Adjuvant (A) | 2019-06-28 | 2019-07-04 | EW EuroEwing 2012 Arm A VIDE | 02 | N | TRIAL UNSPECIFIED | 101673563 |
| 190009586 | 190002776 | null | null | null | null | 2018-02-18 | VIDE | null | null | NOT MATCHED | 100381543 |